Background: Emerging evidence suggested that statins might decrease the risk of cancer. This study examined the associations of statin use with the risk of main urologic cancer, and a sex-specific relationship between statin use and the risk of cancer was also evaluated. Methods: A literature search in PubMed, MEDLINE, and Web of Science databases was undertaken through February 2017 evaluating the association between statin use and risk of main urologic cancer. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using random-effects model. In addition, we also estimated RR ratios (RRRs) between men and women. Results: A total of 30 cohort studies contributed to the analysis. The results of the meta-analysis showed that statin users did not experience a significantly decreased risk for developing kidney cancer in both women and men (RR = 1.01, 95% CI = 0.91-1.11). Statin use in women had the reduced tendency for the risk of kidney cancer, but statin use in men had an adverse tendency for the risk of this disease (Women: RR = 0.98, 95% CI = 0.85-1.12; Men: RR = 1.09, 95% CI = 0.99-1.19). The pooled multiple-adjusted women-to-men RRR for incident kidney cancer was 0.90 (95% CI = 0.75-1.05). Compared to non-users, statin users yielded the reduced risk of total, advanced, high-grade, and low-grade prostate cancer by approximately 12%, 18%, 14% and 7% (Total: RR = 0.88, 95% CI = 0.84-0.93; Advanced: RR = 0.82, 95% CI = 0.70-0.95; High-grade: RR = 0.86, 95% CI = 0.68-0.99; Low-grade: RR = 0.93, 95% CI = 0.86-0.99), whereas the significant effects were not observed for bladder cancer (RR = 1.03, 95% CI = 0.88-1.17). Conclusions: The results found that sex difference could affect the association of statin use with the risk of kidney cancer. The statin use could reduce the risk of prostate cancer but no associations were found between statin use and bladder cancer.